<SEC-DOCUMENT>0001628280-24-007217.txt : 20240227
<SEC-HEADER>0001628280-24-007217.hdr.sgml : 20240227
<ACCEPTANCE-DATETIME>20240227161256
ACCESSION NUMBER:		0001628280-24-007217
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240227
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240227
DATE AS OF CHANGE:		20240227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zai Lab Ltd
		CENTRAL INDEX KEY:			0001704292
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38205
		FILM NUMBER:		24686857

	BUSINESS ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862161632588

	MAIL ADDRESS:	
		STREET 1:		4560 JINKE ROAD
		STREET 2:		BLDG. 1, 4F, PUDONG
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zlab-20240227.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zlab-20240227</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-24">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001704292</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zlab-20240227.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001704292</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001704292</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001704292</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-27</xbrli:startDate><xbrli:endDate>2024-02-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i65b41692435948cd9de0d8b07d5e9b44_1"></div><div style="min-height:9.72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:80%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:80%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">CURRENT REPORT</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:90%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:80%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 27, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:80%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ZAI LAB LIMITED</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:80%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:80%">________________________</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Cayman Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38205</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-1144595</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">4560 Jinke Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Bldg. 1, Fourth Floor, Pudong</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Shanghai</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-10">China</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">201210</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">314 Main Street<br/>4th Floor, Suite 100<br/>Cambridge, MA, USA</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">02142</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">+<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">86 21</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">6163 2588</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:90%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:90%">Not Applicable</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name of each exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">ZLAB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">Ordinary Shares, par value $0.000006 per share*</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">9688</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Stock Exchange of Hong Kong Limited</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:22.5pt">Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.973%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:9.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65b41692435948cd9de0d8b07d5e9b44_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;27, 2024, Zai Lab Limited issued a press release announcing its financial results for the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in this report,&#160;including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="i65b41692435948cd9de0d8b07d5e9b44_13"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zlab-20240227x8kex991.htm">Press Release issued by Zai Lab Limited on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="zlab-20240227x8kex991.htm">February 27, 2024</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this Current Report on Form&#160;8-K&#160;is formatted in Inline XBRL</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i65b41692435948cd9de0d8b07d5e9b44_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZAI LAB LIMITED</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Yajing Chen</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yajing Chen</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: February&#160;27, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>zlab-20240227x8kex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="-sec-extract:summary;margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_111"></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Zai Lab Announces Full-Year 2023</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Financial Results and Recent Corporate Updates</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth&#59; 31% y-o-y growth at constant exchange rate (CER)</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">VYVGART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%"> (efgartigimod alfa injection) was launched in September 2023 in China and we estimate that nearly 1,000 patients were treated through the fourth quarter before its listing on China&#8217;s National Reimbursement Drug List (NRDL)</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">We estimate that nearly 1,000 new patients were treated with VYVGART in January 2024 alone&#59; expect VYVGART product sales to exceed $70.0 million in 2024</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">Regulatory reviews ongoing for sulbactam-durlobactam, efgartigimod SC and repotrectinib&#59; up to four new regulatory submissions expected in 2024</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">Strong balance sheet with a cash position of $807.6 million as of December&#160;31, 2023, compared to $1.0 billion as of December&#160;31, 2022</font></div><div style="margin-top:9pt;padding-left:14.4pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;padding-left:13pt">Company to host conference call and webcast on February 28, 2024, at 8&#58;00 a.m. ET (9&#58;00 p.m. HKT)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">SHANGHAI, China and CAMBRIDGE, Mass., February&#160;27, 2024 -- Zai Lab Limited (NASDAQ&#58; ZLAB&#59; HKEX&#58; 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate updates. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;We made excellent progress on several key strategic priorities in 2023, notably the launch of VYVGART in China for generalized myasthenia gravis (gMG) in September and the drug&#8217;s successful inclusion on China&#8217;s NRDL for this indication effective January 1, 2024,&#8221; said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. &#8220;The launch is off to an impressive start with more patients treated with VYVGART in January than the last four months of 2023 combined, fueled by high physician adoption and increased patient access as hospitals add VYVGART to formularies. Looking ahead, we expect strong commercial performance across our portfolio this year, and are preparing for three new potential launches in 2024. We are also excited by the progress of our late-stage pipeline and our growing global early-stage development efforts. We are on track to achieve the objectives outlined in our five-year strategic plan and to position Zai Lab as a high-growth, profitable and innovative biotech company.&#8221;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;We are focused on achieving three corporate objectives,&#8221; said Josh Smiley, President and Chief Operating Officer of Zai Lab. &#8220;First, we seek to accelerate top-line growth supported by multiple launches of new products and indications over the next two to three years. Second, we aim to reach corporate profitability by the end of 2025 through revenue growth and continued focus on efficiency and productivity. Third, we are committed to building a global portfolio through our internal discovery activities and strategic business development. These corporate objectives capture our vision for Zai Lab, where we lead with innovation, grow with purpose, and deliver on our mission of improving patient lives globally,&#8221; Mr. Smiley concluded.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Full-Year 2023 Financial Results</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Product revenue </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">was $266.7 million in 2023, compared to $212.7 million in 2022, representing 25% y-o-y growth </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">and 31% y-o-y growth at CER.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> This increase was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effects from the COVID-19 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">pandemic, partially offset by an increase in sales rebates to distributors and the effects on hospital and physician practices from the recent industry-wide anti-corruption enforcement efforts in China in the second half of 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">. </font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Sales rebates to distributors resulting from price reductions in connection with NRDL listings were $13.0 million in 2023, up from $5.3 million in 2022, driven by an increased number of new and renewed NRDL listings. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-indent:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Key Highlights by Commercial Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">s</font></div><div style="margin-top:9pt;text-indent:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">ZEJULA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">$168.8 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">million in 2023, which increased 16% y-o-y </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">from $145.2</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> in 2022.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">The increase was driven by increased hospital sales in first-line ovarian cancer and duration of treatment prolongment, partially offset by sales rebates in connection with the renewal in the NRDL.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">ZEJULA continues to be the leading PARP inhibitor in hospital sales for ovarian cancer in China, in its third year on the NRDL.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">ZEJULA&#8217;s NRDL listing was renewed for the maintenance treatment of adult patients with first-line and recurrent ovarian cancer, effective January 1, 2024.</font></div><div style="margin-top:9pt;text-indent:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">VYVGART</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">$10.0</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> million in 2023, compared to nil in 2022.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">We successfully launched VYVGART for the treatment of adult patients with gMG, who are anti-acetylcholine receptor (AChR) antibody positive, in September 2023. </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">We estimate that nearly 1,000 patients were treated from launch through the fourth quarter of 2023. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">VYVGART was added to the NRDL for the treatment of gMG, effective January 1, 2024. </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">We estimate that nearly 1,000 new patients were treated in January 2024 alone driven by positive physician and patient reception as well as increased patient access as VYVGART is added to hospital formularies.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:16pt">We are expecting more than $70.0 million in VYVGART revenue in 2024.</font></div><div style="margin-top:9pt;padding-left:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">OPTUNE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">$47.0 million in 2023, which was relatively flat compared to $47.3 million in 2022.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Continued growth in supplemental insurance coverage was offset by the effects of industry-wide anti-corruption efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:139%">. </font></div><div style="margin-top:9pt;padding-left:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">QINLOCK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">$19.2 million in 2023, which increased 29% y-o-y from $15.0 million in 2022.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Growth was supported by its inclusion in the NRDL in the first quarter of 2023 for the fourth-line treatment of advanced gastrointestinal stromal tumors (GIST), partially offset by sales rebates in connection with the NRDL listing.</font></div><div style="margin-top:9pt;padding-left:17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">NUZYRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div><div style="margin-top:3pt;padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">$21.7</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> milli</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">on in 2023, which increased by 316% y-o-y from $5.2 million in 2022.</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Growth was driven by the initial inclusion of NUZYRA (IV formulation) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in the NRDL in the first quarter of 2023. </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">The oral formulation of NUZYRA was added to the NRDL for these indications, effective January 1, 2024, which we expect to further increase patient access.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Research and Development (R&#38;D) expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">were $265.9 million for 2023, compared to $286.4 million for 2022. This decrease was primarily due to decreased upfront and milestone payments for our license and collaboration agreements, partially offset by an increase in personnel compensation and related costs.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Selling, General and Administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> were $281.6 million for 2023, compared to $259.0 million for 2022. This increase was primarily due to higher general selling expenses related to commercial operations to support the launch of VYVGART, partially offset by a decrease in professional services fees.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Net loss </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">was $334.6 million for 2023, or a loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share (&#8220;ADS&#8221;) of $3.46), compared to a net loss of $443.3 million for 2022, or a loss per ordinary share of $0.46 (or loss per ADS of $4.63). The decrease in net loss was primarily due to product revenue growing faster than net operating expenses, increased interest income, and decreased foreign currency loss. </font></div><div style="margin-top:6pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Cash and cash equivalents, short-term investments and restricted cash </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">totaled $807.6 million as of December&#160;31, 2023, compared to $1.0 billion as of December&#160;31, 2022. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">2024 Strategic Priorities</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Zai Lab will focus on the following strategic priorities in 2024 to drive innovation in China and beyond&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Commercial Execution</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Drive VYVGART ramp-up in gMG in its first year of NRDL inclusion and increase access via hospital listing</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Maintain ZEJULA leadership position in ovarian cancer in China</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Continue to grow supplemental insurance coverage for OPTUNE GIO</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> in glioblastoma (GBM)</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Successfully launch additional products (up to 3) from our innovative pipeline</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Clinical Data and Regulatory Actions</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Potential China approvals&#58; </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Sulbactam-durlobactam in infections caused by susceptible isolates of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Acinetobacter baumannii-calcoaceticus </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">complex</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Efgartigimod SC in gMG</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Repotrectinib in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">ROS1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-positive NSCLC</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Planned China submissions&#58; </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Efgartigimod SC in chronic inflammatory demyelinating polyneuropathy (CIDP)</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Adagrasib in second-line+ NSCLC</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Tisotumab vedotin in second-line+ cervical cancer </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Tumor Treating Fields in second-line+ NSCLC</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Key clinical data readouts&#58; </font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Tumor Treating Fields in first-line brain metastases from NSCLC (METIS) and first-line locally advanced pancreatic cancer (PANOVA-3)</font></div><div style="padding-left:38pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Adagrasib in first-line NSCLC and second-line+ NSCLC</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Clinical Development </font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Join the global Phase 3 registrational study of efgartigimod in thyroid eye disease (TED) in Greater China</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Join the global Phase 3 ADEPT-2 and ADEPT-3 studies of xanomeline-trospium (or KarXT) in Alzheimer&#8217;s disease psychosis (ADP) in Greater China</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Complete enrollment in the China bridging Phase 3 study of xanomeline-trospium (or KarXT) in schizophrenia</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Advance ZL-1102 (IL-17 Humabody</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">) into global Phase 2 development in chronic plaque psoriasis (CPP)</font></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Enroll patients in the global Phase 1 study for ZL-1310 (DLL3 ADC) in small cell lung cancer (SCLC)</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:139%"> </font><font style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:139%">Mainland China, Hong Kong, Macau, and Taiwan (collectively, Greater China)</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:139%">.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Recent Pipeline Highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Below are key product updates since our last earnings release&#58;</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Oncology Pipeline</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Tumor Treating Fields&#58; </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In January 2024, Zai Lab partner Novocure announced that the U.S. Food and Drug Administration (FDA) had accepted for filing its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields therapy together with standard systemic therapies for the treatment of NSCLC, following progression on or after platinum-based therapy. We are preparing a similar submission for this indication, with a goal to submit a Marketing Authorization Application (MAA) to the National Medical Products Administration (NMPA) in 2024.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Repotrectinib (ROS1&#47;TRK)&#58; </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In February 2024, Zai Lab partner Bristol-Myers Squibb (BMS) announced that, based on the results of the TRIDENT-1 trial, the FDA has accepted its supplemental NDA (sNDA) for repotrectinib for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a&#160;neurotrophic tyrosine receptor kinase (NTRK)&#160;gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. The application was granted priority review status, with a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2024.</font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In November 2023, BMS announced that, based on results from the TRIDENT-1 trial, the FDA approved repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Adagrasib (KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">)</font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In February 2024, Zai Lab partner BMS announced that, based on the results of the KRYSTAL-1 trial, the FDA has accepted its sNDA for adagrasib in combination with cetuximab for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC). The application was granted priority review status, with a PDUFA goal date of June 21, 2024. We are participating in the global confirmatory Phase 3 KRYSTAL-10 study in second-line KRAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-mutated CRC in Greater China.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Bemarituzumab (FGFR2b)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China. We expect the first patient in Greater China to be treated in the first quarter of 2024.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">ZL-1310 (DLL3 ADC)&#58; </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">Zai Lab is currently enrolling patients in the United States and China in the global Phase 1 study in relapsed and refractory second-line+ SCLC who have progressed after platinum-based treatment.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Autoimmune Disorders, Infectious Disease, and Neuroscience Pipeline</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Efgartigimod (FcRn)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In February 2024, argenx announced that the FDA has accepted the supplemental Biologics License Application (sBLA) for efgartigimod SC for the treatment of CIDP with priority review. The application has been granted a PDUFA goal date of June 21, 2024. </font></div><div style="padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">We plan to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.</font></div><div style="margin-top:9pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:14.35pt">Xanomeline-Trospium (or KarXT) (M1&#47;M4-agonist)&#58; </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In November 2023, Karuna announced that the FDA has accepted its NDA for </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">xanomeline-trospium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> for the treatment of schizophrenia in adults. The application has been granted a PDUFA goal date of September 26, 2024. We continue to enroll patients in the registrational bridging study in mainland China, and we expect to complete the study this year. </font></div><div style="margin-top:3pt;padding-left:39.7pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:16pt">In November 2023, Karuna announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">xanomeline-trospium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">xanomeline-trospium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> was not associated with increases in blood pressure.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Anticipated Major Milestones in 2024</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Oncology</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Tumor Treating Fields </font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to submit an MAA to the NMPA in second-line+ NSCLC, following progression on or after platinum-based therapy.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab partner Novocure to provide a topline data readout from the phase 3 METIS clinical trial in brain metastases from NSCLC in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> the first quarter of </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2024. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are participating in the study in Greater China.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Novocure to provide a topline data readout from the phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer in the fourth quarter of 2024. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We are participating in the study in Greater China.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">R</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">epotrectinib (ROS1&#47;TRK)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Potential NMPA </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">approval of the NDA in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">locally advanced or metastatic ROS1-positive NSCLC.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Adagrasib (KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to submit an NDA to the NMPA in second-line+ KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-mutated NSCLC. </font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to join the global Phase 3 KRYSTAL-7 study in first-line KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-mutated NSCLC with Tumor Proportion Score (TPS) &#8805; 50% in Greater China in the second half of 2024.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab partner Mirati, a BMS company, to provide a clinical data update for the global confirmatory Phase 3 KRYSTAL-12 study in second-line+ KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-mutated NSCLC. We are participating in the study in Greater China.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Mirati to provide a clinical data update for the global Phase 2 KRYSTAL-17 study in first-line KRAS</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">-mutated NSCLC with TPS &#60; 50%.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Tisotumab Vedotin (Tissue Factor ADC)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to submit an NDA to the NMPA in second-line+ cervical cancer. </font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Neuroscience, Autoimmune Disorders, and Infectious Diseases (NSAiID)</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Efgartigimod (FcRn)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Potential NMPA approval of the sBLA for efgartigimod SC in gMG.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab partner argenx to initiate a registrational study of efgartigimod in TED. Zai Lab plans to participate in the study in Greater China in the second half of 2024.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Sulbactam-Durlobactam (SUL-DUR)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Potential NMPA approval of the NDA in infections caused by susceptible isolates of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Acinetobacter baumannii-calcoaceticus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> complex.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Xanomeline-Trospium (or KarXT) (M1&#47;M4-agonist)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to join the global Phase 3 ADEPT-2 and ADEPT-3 studies in ADP in Greater China in mid-year.</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab partner Karuna to report topline data from the EMERGENT-4 and EMERGENT-5 trials evaluating the long-term safety for treatment of schizophrenia in the second half of 2024.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">ZL-1102 (IL-17 Humabody</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">)</font></div><div style="margin-top:3pt;padding-left:17.85pt;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.35pt">Zai Lab to initiate a global Phase 2 study in mild-to-moderate chronic plaque psoriasis in mid-year.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Conference Call and Webcast Information </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Zai Lab will host a live conference call and webcast tomorrow, February 28, 2024, at 8&#58;00 a.m. ET (9&#58;00 p.m. HKT). Listeners may access the live webcast by visiting the Company&#8217;s website at http&#58;&#47;&#47;ir.zailaboratory.com. Participants must register in advance of the conference call. </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Details are as follows&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Registration Link&#58; https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BIa1fd72e50c9e4117b696c49bdfa9f83b</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">A replay will be available shortly after the call and can be accessed by visiting the Company&#8217;s website.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">About Zai Lab</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Zai Lab&#160;(NASDAQ&#58; ZLAB&#59; HKEX&#58; 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in&#160;China&#160;and&#160;the United States. We are&#160;focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">For additional information about Zai Lab, please visit&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">www.zailaboratory.com</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;or follow us at&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">www.twitter.com&#47;ZaiLab_Global</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Non-GAAP Measures </font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition to results presented in accordance with GAAP, we disclose growth rates that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, which are non-GAAP measures. We believe that these non-GAAP measures are important for an understanding of the performance of our business operations and financial results and provide investors with an additional perspective on trends. Although we believe the non-GAAP financial measures enhance investors&#8217; understanding of our business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Zai Lab Forward-Looking Statements</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">This press release contains forward-looking statements relating to our strategy and plans&#59; potential of and expectations for our business and pipeline programs&#59; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, clinical stage products, revenue growth, profitability, and cash flow)&#59; clinical development programs and related clinical trials&#59; clinical trial data, data readouts, and presentations&#59; risks and uncertainties associated with drug development and commercialization&#59; regulatory discussions, submissions, filings, and approvals and the timing thereof&#59; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners&#59; the anticipated benefits and potential of investments, collaborations, and business development activities&#59; our future financial and operating results&#59; and financial guidance, including with respect to our planned sources and uses of cash and our expected path to profitability. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products&#59; (2) our ability to obtain funding for our operations and business initiatives&#59; (3) the results of our clinical and pre-clinical development of our product candidates&#59; (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates&#59; (5) risks related to doing business in China&#59; and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our SEC filings can be found on our website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">www.zailaboratory.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> and on the SEC&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">www.SEC.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">For more information, please contact&#58;</font></div><div style="margin-top:9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Investor Relations&#58;</font></div><div style="margin-top:3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Christine Chiou &#47; Lina Zhang</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">+1 (917) 886-6929 &#47; +86 136 8257 6943</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">christine.chiou1&#64;zailaboratory.com &#47; lina.zhang&#64;zailaboratory.com</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Media&#58;</font></div><div style="margin-top:3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Shaun Maccoun &#47; Xiaoyu Chen</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">+1 (415) 317-7255 &#47; +86 185 0015 5011</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">shaun.maccoun&#64;zailaboratory.com &#47; xiaoyu.chen&#64;zailaboratory.com</font></div><div><img alt="image_1.jpg" src="image_1.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%">Zai Lab Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:145%"> </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zai Lab Limited</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">(in thousands of U.S. dollars (&#8220;$&#8221;), except for number of shares and per share data)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790,151&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008,470&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,300&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for credit loss of $17 and $11 as of December&#160;31, 2023 and 2022, respectively)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,963&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,608&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,827&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepayments and other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,995&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,674&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">939,606&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,124,336&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash, non-current</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">803&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:31.5pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,431&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepayments for equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,396&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,734&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,863&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,844&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land use rights, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,069&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,892&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,511&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term deposits</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,396&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036,295</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,220,140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,991&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,104&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,972&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,818&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,067&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139,842&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,738&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,360&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,047&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">240,177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174,545</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitments and contingencies </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 32.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ordinary shares (par value of $0.000006 per share&#59; 5,000,000,000 shares authorized, 977,151,270 and 962,455,850 shares issued as of December&#160;31, 2023 and 2022, respectively&#59; 972,239,070 and 960,219,570 shares issued and outstanding as of December&#160;31, 2023 and 2022, respectively)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975,302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893,120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,195,980)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,861,360)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,626&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,685&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock (at cost, 4,912,200 and 2,236,280 shares as of December&#160;31, 2023 and 2022,  respectively)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,836)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,856)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">796,118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,045,595</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,036,295</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,220,140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zai Lab Limited</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands of $, except for number of shares and per share data)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,719&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,105&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,368&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266,719&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,040&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,312&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95,816)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(74,018)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,239)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265,868)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(286,408)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(573,306)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(281,608)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(258,971)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218,831)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of intellectual property</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366,573)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(404,357)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(700,064)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,582&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,190&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency (loss) gain</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,850)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,403)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,661&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,006&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,113&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,201)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax and share of loss from equity method investment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(334,620)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(443,065)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(703,414)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share of loss from equity method investment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,057)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(334,620)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(443,286)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(704,471)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss per share &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.35)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.46)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.76)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating net loss per ordinary share &#8212; basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">966,394,130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958,067,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">929,921,120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#58; Basic and diluted net loss per ordinary share, weighted average number of ordinary shares for the year ended December 31, 2021 have been retrospectively adjusted as a result of the Share Subdivision that became effective on March 30, 2022. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zai Lab Limited</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands of $) </font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(334,620)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(443,286)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(704,471)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax of nil&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,941&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,121)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(322,679)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(393,956)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(713,592)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><div id="i33cef3dd3ccc491a92bbeda0b9e0f67d_104"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:18pt"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zai Lab Limited</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Measures</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of $)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year over Year % Growth</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As reported</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At CER*</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,719&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,672&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366,573)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(404,357)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* The growth rates at constant exchange rates (CER) were calculated assuming the same foreign currency exchange rates were in effect for the current and prior year periods. </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zlab-20240227.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:92c2a195-5c49-4f50-b45e-60628841c70f,g:be8b84bb-0548-4d00-bd5e-48457989e733-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zlab="http://zailab.com/20240227" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://zailab.com/20240227">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zlab-20240227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zlab-20240227_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zlab-20240227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://zailab.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>zlab-20240227_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:92c2a195-5c49-4f50-b45e-60628841c70f,g:be8b84bb-0548-4d00-bd5e-48457989e733-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://zailab.com/role/Cover" xlink:type="simple" xlink:href="zlab-20240227.xsd#Cover"/>
  <link:definitionLink xlink:role="http://zailab.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f462977a-efae-4b93-81c0-0596978d1928_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:to="loc_us-gaap_ClassOfStockDomain_f462977a-efae-4b93-81c0-0596978d1928_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:to="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_a6cb80cf-ff66-4b3c-a628-3c75c72e746d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:to="loc_dei_AdrMember_a6cb80cf-ff66-4b3c-a628-3c75c72e746d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8971f1b-7077-43ca-a6b2-85b8dc4aecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:to="loc_us-gaap_CommonStockMember_f8971f1b-7077-43ca-a6b2-85b8dc4aecd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fd2f5f01-fcb8-4389-b09d-2d6f5ee891af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_DocumentType_fd2f5f01-fcb8-4389-b09d-2d6f5ee891af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5dab0eed-3b8d-4a01-82b9-965123867e37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_DocumentPeriodEndDate_5dab0eed-3b8d-4a01-82b9-965123867e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f6f00a52-332d-4c2a-91bc-ceea6be7fa0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityRegistrantName_f6f00a52-332d-4c2a-91bc-ceea6be7fa0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8ff6e109-0abc-41db-b4b8-38275741911e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8ff6e109-0abc-41db-b4b8-38275741911e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1eb9ed56-221f-4511-9cc8-07cf2db77e9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityFileNumber_1eb9ed56-221f-4511-9cc8-07cf2db77e9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_229e2283-6397-4067-a035-3a5fd3fd8a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityTaxIdentificationNumber_229e2283-6397-4067-a035-3a5fd3fd8a5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_aed46100-50fe-46e3-a05d-d316b1c33178" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressAddressLine1_aed46100-50fe-46e3-a05d-d316b1c33178" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e0805507-8573-45e9-96d9-9607c18dce9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressAddressLine2_e0805507-8573-45e9-96d9-9607c18dce9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c23dcc74-8b1b-49ca-8f86-0ed1262880ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressCityOrTown_c23dcc74-8b1b-49ca-8f86-0ed1262880ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_f228eb87-a9d6-4852-9c41-80cfe58a55af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressCountry_f228eb87-a9d6-4852-9c41-80cfe58a55af" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a5997030-5a00-414d-8967-4303f63cac89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressPostalZipCode_a5997030-5a00-414d-8967-4303f63cac89" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_25f06d64-daff-456c-a984-b12f537042a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_CityAreaCode_25f06d64-daff-456c-a984-b12f537042a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_01671ad7-b47c-4804-b626-1e3767d1bd6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_LocalPhoneNumber_01671ad7-b47c-4804-b626-1e3767d1bd6c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_62835f43-9c95-4d2c-8af4-9db3cc5528e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_WrittenCommunications_62835f43-9c95-4d2c-8af4-9db3cc5528e2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a38d013c-e344-48c1-86bc-8880c8390369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_SolicitingMaterial_a38d013c-e344-48c1-86bc-8880c8390369" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_79126d5b-9a71-44ac-a234-f8ee1126dd23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_PreCommencementTenderOffer_79126d5b-9a71-44ac-a234-f8ee1126dd23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cf42b0ce-6ec1-4b3a-bf71-7321a1079497" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cf42b0ce-6ec1-4b3a-bf71-7321a1079497" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cb193656-63a5-49f8-9cac-274c38e3c53e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_Security12bTitle_cb193656-63a5-49f8-9cac-274c38e3c53e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b038c95e-b3c6-4a19-b03b-6cb6003b86ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_TradingSymbol_b038c95e-b3c6-4a19-b03b-6cb6003b86ae" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_55bc3900-63a4-45f6-90a4-9743480665d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_SecurityExchangeName_55bc3900-63a4-45f6-90a4-9743480665d3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a0ad549-fb89-4e2a-949c-d53a8544747e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a0ad549-fb89-4e2a-949c-d53a8544747e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae07c391-7689-42d8-bf51-e2e4c4647948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_AmendmentFlag_ae07c391-7689-42d8-bf51-e2e4c4647948" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2404b7d1-4cd0-4744-8a59-1b4eb8eede78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityCentralIndexKey_2404b7d1-4cd0-4744-8a59-1b4eb8eede78" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>zlab-20240227_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:92c2a195-5c49-4f50-b45e-60628841c70f,g:be8b84bb-0548-4d00-bd5e-48457989e733-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_aab50a72-56da-4e68-bc5f-d875f8796255_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3f7cd7ca-eaaf-441e-8b87-09685d63b47f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b833483b-028b-4bcb-86c1-bfc90b929698_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_388d5906-bb38-486d-9baa-9878fae0e60c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a5985990-e82d-494d-a64a-b403b1e42bd0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fb39c5c5-c252-4d3b-b511-b1a3c981b641_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3d26e88-9327-4179-a46c-8fab544982ef_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d61c7a8d-bcc2-47c4-9496-58469fe291a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f8d0930e-8689-41ed-ab54-8ababcb3ba38_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6988e67b-f273-43b9-9fd5-2f45de1dd7af_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_591ca157-e0b4-472d-89b6-0c0396e595ef_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AdrMember_2503e66a-0e5b-4a56-98e1-e853fbe061e1_terseLabel_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADR</link:label>
    <link:label id="lab_dei_AdrMember_label_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_77a082b2-f686-418b-bbba-25675bcb1a2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bb6d0c39-a5a4-4640-aba0-f5d7e281ec83_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ebb6f861-2f0d-413d-bf5d-95816bf3e854_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_219972e2-75ea-42c5-9c7c-e17e73fdc54e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4a44bdf1-f961-46ed-8700-ca9e35322e35_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5ab5bccf-9559-4d08-ba11-1b7b7fd776f9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ffce9cdc-4bf1-4791-869b-09d8b7613f3e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d6132302-c53e-4bc3-bba6-6368b51e83f3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2b7067ab-074b-4457-acfa-695cd93d1db1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3435541a-cb5c-4064-bd40-f8a7e6848f6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_713a8a1b-8209-44c5-8e76-cdcac718a8a7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_3b3e085b-84f2-4525-b8aa-c26376ff6289_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_ddc996c8-5948-407d-9d2f-68c203124170_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9ee64aa9-a5ca-47f3-83e3-175b46e0e237_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_a9d4d413-825a-4788-a242-7423f26f3250_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ad2561d2-d9f1-40f7-a563-c25007099a92_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9d5eb64e-18fe-4104-87bd-d76c4420d934_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>zlab-20240227_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:92c2a195-5c49-4f50-b45e-60628841c70f,g:be8b84bb-0548-4d00-bd5e-48457989e733-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://zailab.com/role/Cover" xlink:type="simple" xlink:href="zlab-20240227.xsd#Cover"/>
  <link:presentationLink xlink:role="http://zailab.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_37e5f527-2003-4efd-8644-61662490d89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_37e5f527-2003-4efd-8644-61662490d89d" xlink:to="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f462977a-efae-4b93-81c0-0596978d1928" xlink:to="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_a6cb80cf-ff66-4b3c-a628-3c75c72e746d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:to="loc_dei_AdrMember_a6cb80cf-ff66-4b3c-a628-3c75c72e746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f8971f1b-7077-43ca-a6b2-85b8dc4aecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6e75185d-e8b6-419e-8fa6-79328a41a2eb" xlink:to="loc_us-gaap_CommonStockMember_f8971f1b-7077-43ca-a6b2-85b8dc4aecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_be54e705-c24c-48ec-8714-cdfc76a8b2fd" xlink:to="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fd2f5f01-fcb8-4389-b09d-2d6f5ee891af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_DocumentType_fd2f5f01-fcb8-4389-b09d-2d6f5ee891af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5dab0eed-3b8d-4a01-82b9-965123867e37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_DocumentPeriodEndDate_5dab0eed-3b8d-4a01-82b9-965123867e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f6f00a52-332d-4c2a-91bc-ceea6be7fa0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityRegistrantName_f6f00a52-332d-4c2a-91bc-ceea6be7fa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8ff6e109-0abc-41db-b4b8-38275741911e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8ff6e109-0abc-41db-b4b8-38275741911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1eb9ed56-221f-4511-9cc8-07cf2db77e9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityFileNumber_1eb9ed56-221f-4511-9cc8-07cf2db77e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_229e2283-6397-4067-a035-3a5fd3fd8a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityTaxIdentificationNumber_229e2283-6397-4067-a035-3a5fd3fd8a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_aed46100-50fe-46e3-a05d-d316b1c33178" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressAddressLine1_aed46100-50fe-46e3-a05d-d316b1c33178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e0805507-8573-45e9-96d9-9607c18dce9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressAddressLine2_e0805507-8573-45e9-96d9-9607c18dce9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c23dcc74-8b1b-49ca-8f86-0ed1262880ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressCityOrTown_c23dcc74-8b1b-49ca-8f86-0ed1262880ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_f228eb87-a9d6-4852-9c41-80cfe58a55af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressCountry_f228eb87-a9d6-4852-9c41-80cfe58a55af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a5997030-5a00-414d-8967-4303f63cac89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityAddressPostalZipCode_a5997030-5a00-414d-8967-4303f63cac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_25f06d64-daff-456c-a984-b12f537042a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_CityAreaCode_25f06d64-daff-456c-a984-b12f537042a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_01671ad7-b47c-4804-b626-1e3767d1bd6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_LocalPhoneNumber_01671ad7-b47c-4804-b626-1e3767d1bd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_62835f43-9c95-4d2c-8af4-9db3cc5528e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_WrittenCommunications_62835f43-9c95-4d2c-8af4-9db3cc5528e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a38d013c-e344-48c1-86bc-8880c8390369" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_SolicitingMaterial_a38d013c-e344-48c1-86bc-8880c8390369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_79126d5b-9a71-44ac-a234-f8ee1126dd23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_PreCommencementTenderOffer_79126d5b-9a71-44ac-a234-f8ee1126dd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_cf42b0ce-6ec1-4b3a-bf71-7321a1079497" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_cf42b0ce-6ec1-4b3a-bf71-7321a1079497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cb193656-63a5-49f8-9cac-274c38e3c53e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_Security12bTitle_cb193656-63a5-49f8-9cac-274c38e3c53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b038c95e-b3c6-4a19-b03b-6cb6003b86ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_TradingSymbol_b038c95e-b3c6-4a19-b03b-6cb6003b86ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_55bc3900-63a4-45f6-90a4-9743480665d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_SecurityExchangeName_55bc3900-63a4-45f6-90a4-9743480665d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a0ad549-fb89-4e2a-949c-d53a8544747e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a0ad549-fb89-4e2a-949c-d53a8544747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae07c391-7689-42d8-bf51-e2e4c4647948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_AmendmentFlag_ae07c391-7689-42d8-bf51-e2e4c4647948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2404b7d1-4cd0-4744-8a59-1b4eb8eede78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_167bda30-ea2e-4792-822c-96af7771403c" xlink:to="loc_dei_EntityCentralIndexKey_2404b7d1-4cd0-4744-8a59-1b4eb8eede78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" !N 4H# 2(  A$! Q$!_\0
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MQX7NKN5GDA9/O0;VY9=IR,^E?K1;@%<^_>O;P6,^N4_:)6/R7BCAS$\+YQ+
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M_P :IC_\&W_[+'3_ (7#XW7ZW$'_ ,;J>;/NG*/V'@[_ ,_*WW?\ ] \)?\
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M]WL?>OZ8OVM/V3OAK^US\%-7^#_Q*T]9HKRW9M/O?+!DL;H ^7.A[%6P<<9
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M-.MG=:FIQ2L_0_3L1E?A'E=:>$Q->I.=-V;5]UZ(U/\ B(P_8G#;3X2\:_\
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MLS98_7 P !7\_P#^P9^VK;_L,_$C4/BA8_"?3_%&L7%D;2PN;^^,0LXRV7V
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M<&[7?>/F?O4N=HR:A?).*_./P[_P<C?LXW6F!O%7P5\76-YM'[FUDMYHR?\
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M6_\ 8K6_\C7?P[_O4_0^*\=XN.2X5/\ G?Y,_.G_ (.3O^2[?#O_ +%FY_\
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139795006491584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 27,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ZAI LAB LIMITED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1144595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4560 Jinke Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg. 1, Fourth Floor, Pudong<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Shanghai<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">201210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">86 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6163 2588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001704292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">ADR</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZLAB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value $0.000006 per share*<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">9688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( )N!6U@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ FX%;6%C%N1+O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ FX%;6)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " ";
M@5M8*"),XN($  !/%0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ FX%;6)^@&_"Q @  X@P   T
M         ( !)@T  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ";@5M8EXJ[
M',     3 @  "P              @ $"$   7W)E;',O+G)E;'-02P$"% ,4
M    " ";@5M8JL0B%C,!   B @  #P              @ 'K$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ FX%;6"0>FZ*M    ^ $  !H
M     ( !2Q(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ FX%;6&60>9(9 0  SP,  !,              ( !,!,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  >A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zlab-20240227.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://zailab.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="zlab-20240227.htm">zlab-20240227.htm</File>
    <File>zlab-20240227.xsd</File>
    <File>zlab-20240227_def.xml</File>
    <File>zlab-20240227_lab.xml</File>
    <File>zlab-20240227_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zlab-20240227.htm": {
   "nsprefix": "zlab",
   "nsuri": "http://zailab.com/20240227",
   "dts": {
    "inline": {
     "local": [
      "zlab-20240227.htm"
     ]
    },
    "schema": {
     "local": [
      "zlab-20240227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "zlab-20240227_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "zlab-20240227_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zlab-20240227_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 25
   },
   "report": {
    "R1": {
     "role": "http://zailab.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zlab-20240227.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zlab-20240227.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AdrMember",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADR",
        "label": "ADR [Member]",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "CommonStockMember",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://zailab.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-24-007217-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-007217-xbrl.zip
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M=JCXAU-EL]^;/-:P&6>SP2]02P,$%     @ FX%;6%*FB]!G"   $#X  !4
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M.JJ/=5R[[I^8CJZ6OBH6G@J#]0$0+ IP-^Y8]^*"\"0+/J-X8#(W3LX[YK9
MR^?3-R#DJ%;5.JK>7H935YY _RQ;*1^P!J!=9&%UH%)&+,4CJZ7 (C_+U(,O
M:7W_[7G;ZA;(.IK, 74GZ%6]74)]@N'VG[JZ:$\Q39RY\FHA'75124N2-Y9(
MZ%Y8D#:0J(0S2DHM]10MYT'C6Z#U5-0.O LRJEVUCY[&SMN?"W>R<$ U1A^F
M^:Q#PJ/!K*\8 0XRR S=E>.>%MXQMP6R/I^^ 2$G>&7K *'4KCC$0N[R%[A:
M<$FEUQ$KN! I^H6[-^.4)<Q+\%C,1YCD\>\]LUL@['@Z!P1>-;!>SN_Q@G _
MOWZQ.MU]=/\5_/K%_P!02P,$%     @ FX%;6">+/-3%#   N7<  !4   !Z
M;&%B+3(P,C0P,C(W7VQA8BYX;6S575UOVS@6?>^OT&9?=H%A(U$D11;3#KII
MNR@VTQ9-!C/8P<+@EQ*AMA7(2I/\^Z5D.Y%BR2(E6]6\M*Y-79Y[K*/#CTOW
MYU_N%W/ON\Y62;I\?1*\]$\\O92I2I97KT]^N_P Z,DO;UZ\^/EO /SQKZ_G
MWKM4WB[T,O?.,LUSK;R[)+_V\FOM_9YFWY+OW/LRYWF<9@L WI27G:4W#UER
M=9U[T(=HVVS[:?:*00EYP## $C& 8NP#@; &Q">04A3(R(]_NGHE-!44"0%\
MC"A RC?-E&F&*,(1HTQ'85@&G2?+;Z^*/P1?:<^DMUR5_WQ]<IWG-Z].3^_N
M[E[>BVS^,LVN3J'OAZ?;UB>;YO<[[>_"LG7 &#LM/WULNDJ:&IJPP>D?OYY?
MR&N]X"!9KG*^E$4'J^35JGSS/)4\+UGOQ.6UMBC^!;;-0/$6"" (@Y?W*W7R
MYH7GK>G(TKG^JF.O^/NWKQ];NV2G18O3I;XJOMLO.DM2=9'S+#_G0L\-^C):
M_G"C7Y^LDL7-7&_?N\YTW!QVGF6UJ 5*5J ,2('R[VV=G0Z ?R"\^2[6 X K
MT_UT*(S[./UT,+B7Y@FACP^XTLU@R.L;ZOU2C77O/G8U&/KQ$1_JMDAS/A_A
MMGCJI@)Y7KQQ;EYMNBD"[7F8EOUL'MT5J/H^UTNEUT_+6F@O4:]/S*N9TLGL
M_3)/\H<SXWP9GW\T%]S_1S_,.!?8YQ$$F"@.D"84"(ECH&B$8QHQ C&>Y8\W
M]4POP6\7V_[+3CIZ.''(+6_1:*97Z6TFG]QM,6^R+.-6A;_1TR5?Z-4-WUQ@
M8!9#@37R-VN0W@:E5\+T#,Z?3Y]2ZD/D_/CTS"?&3"IK6.;%<"#-GF>?RN[L
MG_2U,L#+U%=:OKQ*OY^::PT%$!8O0/&BE%5[Q-.=+^]MML7),]G!\Z;%J4S-
M6.<F!S7*XRQ=6":4IY;?^YHZT^V)EV9*9V8$VY!"P_WW5BGSY:\V?YF'B(:S
M,(ZDBB0'FO,8(!1H8(:<$? 9H5B14* H=A-S0R\3%?0&XD_;%UX!UKN\2UV%
MW42LK;@'TC6.P-V9ZB'T/4P,$'M3U)$%OR>Q7='O:WPXX0<S0<,0T=!,+2$5
M  DI "4R "*6S!<,,L+H4.$'?RGA?U[JX<(/!@C?B:X?*?Q]3!U$^,%1A-^D
MEI&%'[@(/Q@@_,N,%\M9%P\+D<YG(:4*,Y\ (4(*$"4*,,$Y8#2B,=>^)KZT
M%7LM\M0$O@'GK='9R[E.5[>$>Y-P9-E:YN\DTL9<>PFS'FDT,38F4!5@<X.^
M;OLAF>M/MPNALQG'C&+&?* I5  QI  GB .!_% $&D&A?#>3?0H^->EM'*,
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M.613ZH-<LA9P=*=L2J?)+1O;]=UT_:JODE6>\65>WG?0?+$1U!!$6'. H,2
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MS&Y5?I@.B<=+NV$V7E5=V5V^AT793^RK[G>_0K9UIM0K3H3@Z'_DGC@6(HD
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M8K8"&+MNRK['5-ZG/:;UK!>G;Q;<NC6WGF(7/+)%\(, '^Z.N\H&"0<@@LN
MM"&@[ XPIPP996!@L2@U-:3[]LGJ$?9HQDZ;3]Z^KR@N):C3FN9[&3Y0!+KG
MPM.\MVJAY)^;M*/.5=KT+3?-9Q9S7]+_ZA[X9]*<2!T_N*[2$RMZV=7)A\(
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M[),X\B4.NA#L3(9^@#W&#/91M]Z(0_P6#_%5R.\31@U#&_!CB^+\>T<":JJ
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M3>]I2W?5%D]H7ZE9_R (]5AE!;\5Q(X=^I-IY$ !=SR@>%O&,Z'"NC KO+L
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MNLFEFJ%)>X#X(+'($ ;'!P54'.0[!<QM=_NB0%;=A/X2">_Y& E>!:#\7?G
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M\1Z]QT>X18.PCH$.ZILM?5B[<#DZ_<?WTHD&&K[9NS2XS,DMO O B:/EMV1
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MAN/-V0">P[I"X(#$*/##D;"Q?ZD[9MSY(P[I32'C\&L8NS1A 1^I<@QNXBY
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M$KZEYB=@_DC?"1<T'RFR3Q9FGF^7??)#UW?&\,\@&KIO_P]02P$"% ,4
M" ";@5M8-CQ<GAT0  "D=0  $0              @ $     >FQA8BTR,#(T
M,#(R-RYH=&U02P$"% ,4    " ";@5M8*^Y@]9("  #>"   $0
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%:@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>zlab-20240227_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zlab-20240227.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001704292</identifier>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001704292</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001704292</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-27</startDate>
            <endDate>2024-02-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001704292</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-02-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ZAI LAB LIMITED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38205</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-1144595</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">4560 Jinke Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Bldg. 1, Fourth Floor, Pudong</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Shanghai</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-10">CN</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">201210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">86 21</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">6163 2588</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-18">American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">ZLAB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">Ordinary Shares, par value $0.000006 per share*</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">9688</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
